Back
to sessions
Sep 28
Scientific
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
10:45am - 10:55am ET
-
10:55am - 11:05am ET
A Dose Escalation Study of Papaverine As a Selective Hypoxic Radiosensitizer for Lung Stereotactic Body Radiation Therapy (SBRT) In the Treatment of Early-Stage Non-Small Cell Lung Cancer (NSCLC) and Other Malignancies
Speaker: Jeremy Brownstein, MD, MS - Ohio State University James Cancer Hospital, Columbus -
11:05am - 11:15am ET
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT): Long-Term Outcomes
Speaker: Caroline Oska, MD - Montefiore Einstein Comprehensive Cancer Center, Bronx -
11:15am - 11:25am ET
Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial
Speaker: Linlin Wang, - Cancer Hospital of Shangdong First Medical University, Jinan -
11:25am - 11:35am ETSpeaker: Shumaila Saad, MD - Montefiore Medical Center, Bronx
-
11:35am - 11:45am ET
Association Between Circulating Immunobiomarkers and Survival In Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Chemoradiation (CRT): Longitudinal Analyses from NRG-RTOG 0617
Speaker: Joseph Miccio, MD - Penn State Hershey Medical Center, Hershey